Klaus Baumann

6.9k total citations · 1 hit paper
84 papers, 2.2k citations indexed

About

Klaus Baumann is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Klaus Baumann has authored 84 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Reproductive Medicine, 21 papers in Oncology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Klaus Baumann's work include Ovarian cancer diagnosis and treatment (32 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Hormonal Regulation and Hypertension (10 papers). Klaus Baumann is often cited by papers focused on Ovarian cancer diagnosis and treatment (32 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Hormonal Regulation and Hypertension (10 papers). Klaus Baumann collaborates with scholars based in Germany, United States and Switzerland. Klaus Baumann's co-authors include Andreas du Bois, Sibylle Loibl, Gϋnter von Minckwitz, Nicolaì Maass, Felix E. de Jongh, Marcus Schmidt, Valentina Nekljudova, Michael Andersson, Tanja Čufer and Robert C. Stein and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Klaus Baumann

77 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

2009 504 citations Gϋnter von Minckwitz, Andreas du Bois et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klaus Baumann Germany	22	1.0k	424	421	378	325	84	2.2k
Hitoshi Niikura Japan	30	553 0.5×	725 1.7×	288 0.7×	673 1.8×	72 0.2×	97	2.5k
Luigi Celio Italy	22	1.2k 1.2×	142 0.3×	351 0.8×	244 0.6×	80 0.2×	82	2.2k
Kyosuke Yamada Japan	16	355 0.3×	283 0.7×	133 0.3×	589 1.6×	84 0.3×	52	1.6k
Sylvia Stadlmann Austria	25	502 0.5×	222 0.5×	166 0.4×	610 1.6×	101 0.3×	56	2.0k
Chiara Mignogna Italy	26	340 0.3×	93 0.2×	290 0.7×	500 1.3×	65 0.2×	96	1.7k
Georg Pfeiler Austria	24	952 0.9×	100 0.2×	286 0.7×	532 1.4×	71 0.2×	91	1.7k
Min Ren United States	21	406 0.4×	59 0.1×	322 0.8×	330 0.9×	309 1.0×	80	1.7k
Ken‐Ichiro Yoshida Japan	28	593 0.6×	135 0.3×	769 1.8×	924 2.4×	251 0.8×	118	2.4k
Antonia Martinetti Italy	32	1.5k 1.5×	113 0.3×	618 1.5×	685 1.8×	102 0.3×	121	2.8k
Bae Kwon Jeong South Korea	22	279 0.3×	50 0.1×	348 0.8×	235 0.6×	239 0.7×	80	1.1k

Countries citing papers authored by Klaus Baumann

Since Specialization

Citations

This map shows the geographic impact of Klaus Baumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Baumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Baumann more than expected).

Fields of papers citing papers by Klaus Baumann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Baumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Baumann. The network helps show where Klaus Baumann may publish in the future.

Co-authorship network of co-authors of Klaus Baumann

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Baumann. A scholar is included among the top collaborators of Klaus Baumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Baumann. Klaus Baumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Molino, Caroline de Godoi Rezende Costa, Klaus Baumann, Angélique Sadlon, et al.. (2025). Polypharmacy and Mild Cognitive Impairment in Older Adults: A 3-year Study of DO-HEALTH. Journal of the American Medical Directors Association. 26(6). 105586–105586.

Martin, Andrew, Bhavana Pothuri, I. Vergote, et al.. (2022). 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. Annals of Oncology. 33. S789–S789. 16 indexed citations

Chase, Dana M., Margarita Romeo, Floor Backes, et al.. (2022). Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial. Gynecologic Oncology. 166(3). 494–502. 10 indexed citations

Woelber, Linn, Katharina Prieske, Christine zu Eulenburg, et al.. (2021). Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. Gynecologic Oncology. 164(1). 68–75. 17 indexed citations

Woelber, Linn, Mareike Bommert, Philipp Harter, et al.. (2021). Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. Annals of Surgical Oncology. 28(11). 6696–6704. 2 indexed citations

Prieske, Katharina, Linn Woelber, Mustafa Zelal Muallem, et al.. (2021). Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. Gynecologic Oncology. 161(2). 442–448. 11 indexed citations

Winterhoff, Boris, Stefan Kommoss, Florian Heitz, et al.. (2018). Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.. eScholarship (California Digital Library). 2018. 1093–1102. 5 indexed citations

Harter, Philipp, Jalid Sehouli, Alexander Reuß, et al.. (2016). Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). International Journal of Gynecological Cancer. 26(9). 1636–1641. 5 indexed citations

Piccirillo, Maria Carmela, Giovanni Scambia, Alessandra Bologna, et al.. (2016). The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy. A collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG. Annals of Oncology. 27. iv2–iv2.

10.

Cojocel, C., et al.. (2015). Effects of Aminoglycoside Treatment on Renal Protein Reabsorption and Accumulation. Contributions to nephrology. 42. 196–201.

11.

Mahner, Sven�, J Jueckstock, Felix Hilpert, et al.. (2015). Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study. JNCI Journal of the National Cancer Institute. 107(3). 128 indexed citations

12.

Darb‐Esfahani, Silvia, Gϋnter von Minckwitz, Carsten Denkert, et al.. (2014). Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 14(1). 546–546. 67 indexed citations

13.

Hensley, Martee L., Brigitte A. Barrette, Klaus Baumann, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review. International Journal of Gynecological Cancer. 24(9 Suppl 3). S61–S66. 44 indexed citations

14.

Bois, Andreas du, Anne Floquet, Jae‐Weon Kim, et al.. (2013). Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).. Journal of Clinical Oncology. 31(15_suppl). LBA5503–LBA5503. 49 indexed citations

15.

Baumann, Klaus, Andreas du Bois, Werner Meier, et al.. (2012). A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology. 23(9). 2265–2271. 67 indexed citations

16.

Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations

17.

Reinartz, Silke, Jacobus Pfisterer, Andreas du Bois, et al.. (2009). Suppressive activity rather than frequency of FoxP3+ regulatory T cells is essential for CA-125–specific T-cell activation after abagovomab treatment. Human Immunology. 71(1). 36–44. 5 indexed citations

18.

Ramsay, Jonathan, et al.. (1998). Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. British Journal of Cancer. 77(1). 11–14. 19 indexed citations

19.

Baumann, Klaus, et al.. (1998). Long‐chain polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of children with phenylketonuria after controlled linoleic acid intake. Journal of Inherited Metabolic Disease. 21(4). 373–381. 30 indexed citations

20.

Clarke, Robert, Todd C. Skaar, Klaus Baumann, et al.. (1994). Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Research and Treatment. 31(2-3). 237–248. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact